Title: The relationship between the use of metformin and the risk of pancreatic cancer in patients
with diabetes: A systematic review and meta-analysis
Version: 2 Date: 27 Dec 2022
Reviewer's report:
An upcoming and pertinent area of research with data being available for a decade or so.
The following are suggested to improve the manuscript:
1. The effect of Metformin on Pancreatic Cancer is required to be highlighted in the introduction
rather than diabetes
2. The results need a better description to enhance reader comprehension
3. The discussion also needs to be improves with comparison with more of available literature.
The following maybe added and discussed:
a. Shi YQ, Zhou XC, Du P, Yin MY, Xu L, Chen WJ, Xu CF. Relationships are between
metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic
review and meta-analysis. Medicine (Baltimore). 2020 Sep 11;99(37):e21687. doi: 10.1097/
MD.0000000000021687. PMID: 32925714; PMCID: PMC7489714.
b. Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, Xu C, Liu YH, Yao Y, Li D.
Metformin is associated with survival benefit in pancreatic cancer patients with diabetes:
a systematic review and meta-analysis. Oncotarget. 2017 Apr 11;8(15):25242-25250. doi:
10.18632/oncotarget.15692. PMID: 28445955; PMCID: PMC5421925.
c. Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit
in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.
Oncologist. 2013;18(12):1248-55. doi: 10.1634/theoncologist.2013-0111. Epub 2013 Nov 20.
PMID: 24258613; PMCID: PMC3868417.
d. Amin S, Mhango G, Lin J, Aronson A, Wisnivesky J, Boffetta P, Lucas AL. Metformin
Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing
Diabetes: A Propensity Score Analysis. Am J Gastroenterol. 2016 Sep;111(9):1350-7. doi:
10.1038/ajg.2016.288. Epub 2016 Jul 19. PMID: 27430290; PMCID: PMC5041138.
e. Terasaki F, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka
K. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and
comorbid diabetes mellitus. Langenbecks Arch Surg. 2020 May;405(3):313-324. doi: 10.1007/
s00423-020-01874-3. Epub 2020 May 4. PMID: 32367394.
f. Gong J, Robbins LA, Lugea A, Waldron RT, Jeon CY and Pandol SJ (2014) Diabetes,
pancreatic cancer, and metformin therapy. Front. Physiol. 5:426. doi: 10.3389/fphys.2014.00426
g. Yu H, Zhong X, Gao P, Shi J, Wu Z, Guo Z, Wang Z and Song Y (2019) The Potential
Effect of Metformin on Cancer: An Umbrella Review. Front. Endocrinol. 10:617. doi: 10.3389/
fendo.2019.00617
Title: The relationship between the use of metformin and the risk of pancreatic cancer in patients
with diabetes: A systematic review and meta-analysis
Version: 2 Date: 27 Dec 2022
Reviewer's report:
An upcoming and pertinent area of research with data being available for a decade or so.
The following are suggested to improve the manuscript:
1. The effect of Metformin on Pancreatic Cancer is required to be highlighted in the introduction
rather than diabetes
2. The results need a better description to enhance reader comprehension
3. The discussion also needs to be improves with comparison with more of available literature.
The following maybe added and discussed:
a. Shi YQ, Zhou XC, Du P, Yin MY, Xu L, Chen WJ, Xu CF. Relationships are between
metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic
review and meta-analysis. Medicine (Baltimore). 2020 Sep 11;99(37):e21687. doi: 10.1097/
MD.0000000000021687. PMID: 32925714; PMCID: PMC7489714.
b. Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, Xu C, Liu YH, Yao Y, Li D.
Metformin is associated with survival benefit in pancreatic cancer patients with diabetes:
a systematic review and meta-analysis. Oncotarget. 2017 Apr 11;8(15):25242-25250. doi:
10.18632/oncotarget.15692. PMID: 28445955; PMCID: PMC5421925.
c. Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit
in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.
Oncologist. 2013;18(12):1248-55. doi: 10.1634/theoncologist.2013-0111. Epub 2013 Nov 20.
PMID: 24258613; PMCID: PMC3868417.
d. Amin S, Mhango G, Lin J, Aronson A, Wisnivesky J, Boffetta P, Lucas AL. Metformin
Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing
Diabetes: A Propensity Score Analysis. Am J Gastroenterol. 2016 Sep;111(9):1350-7. doi:
10.1038/ajg.2016.288. Epub 2016 Jul 19. PMID: 27430290; PMCID: PMC5041138.
e. Terasaki F, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka
K. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and
comorbid diabetes mellitus. Langenbecks Arch Surg. 2020 May;405(3):313-324. doi: 10.1007/
s00423-020-01874-3. Epub 2020 May 4. PMID: 32367394.
f. Gong J, Robbins LA, Lugea A, Waldron RT, Jeon CY and Pandol SJ (2014) Diabetes,
pancreatic cancer, and metformin therapy. Front. Physiol. 5:426. doi: 10.3389/fphys.2014.00426
g. Yu H, Zhong X, Gao P, Shi J, Wu Z, Guo Z, Wang Z and Song Y (2019) The Potential
Effect of Metformin on Cancer: An Umbrella Review. Front. Endocrinol. 10:617. doi: 10.3389/
fendo.2019.00617
Please review this paper.
user
Title: The relationship between the use of metformin and the risk of pancreatic cancer in patients
with diabetes: A systematic review and meta-analysis
Version: 2 Date: 27 Dec 2022
Reviewer's report:
An upcoming and pertinent area of research with data being available for a decade or so.
The following are suggested to improve the manuscript:
1. The effect of Metformin on Pancreatic Cancer is required to be highlighted in the introduction
rather than diabetes
2. The results need a better description to enhance reader comprehension
3. The discussion also needs to be improves with comparison with more of available literature.
The following maybe added and discussed:
a. Shi YQ, Zhou XC, Du P, Yin MY, Xu L, Chen WJ, Xu CF. Relationships are between
metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic
review and meta-analysis. Medicine (Baltimore). 2020 Sep 11;99(37):e21687. doi: 10.1097/
MD.0000000000021687. PMID: 32925714; PMCID: PMC7489714.
b. Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, Xu C, Liu YH, Yao Y, Li D.
Metformin is associated with survival benefit in pancreatic cancer patients with diabetes:
a systematic review and meta-analysis. Oncotarget. 2017 Apr 11;8(15):25242-25250. doi:
10.18632/oncotarget.15692. PMID: 28445955; PMCID: PMC5421925.
c. Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit
in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.
Oncologist. 2013;18(12):1248-55. doi: 10.1634/theoncologist.2013-0111. Epub 2013 Nov 20.
PMID: 24258613; PMCID: PMC3868417.
d. Amin S, Mhango G, Lin J, Aronson A, Wisnivesky J, Boffetta P, Lucas AL. Metformin
Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing
Diabetes: A Propensity Score Analysis. Am J Gastroenterol. 2016 Sep;111(9):1350-7. doi:
10.1038/ajg.2016.288. Epub 2016 Jul 19. PMID: 27430290; PMCID: PMC5041138.
e. Terasaki F, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka
K. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and
comorbid diabetes mellitus. Langenbecks Arch Surg. 2020 May;405(3):313-324. doi: 10.1007/
s00423-020-01874-3. Epub 2020 May 4. PMID: 32367394.
f. Gong J, Robbins LA, Lugea A, Waldron RT, Jeon CY and Pandol SJ (2014) Diabetes,
pancreatic cancer, and metformin therapy. Front. Physiol. 5:426. doi: 10.3389/fphys.2014.00426
g. Yu H, Zhong X, Gao P, Shi J, Wu Z, Guo Z, Wang Z and Song Y (2019) The Potential
Effect of Metformin on Cancer: An Umbrella Review. Front. Endocrinol. 10:617. doi: 10.3389/
fendo.2019.00617
assistant